Genomics – achieving all we ever hoped for from medicine?

It was during a press conference at the White House in June 2000 when the Human Genome Project, an international research collaborative, announced the first draft of a human genome had been sequenced, essentially mapping out the blueprint of our DNA.

“We now have the possibility of achieving all we ever hoped for from medicine.” – The then UK Science Minister, Lord Sainsbury

Genomics: A Landmark Moment

It was a landmark moment for medical research. Society stood on the brink of an era of personalised medicine that would change healthcare as we know it. Remarkable is how quickly this feat has been achieved. A mere 50 years after James Watson and Francis Crick discovered the very existence of DNA itself.

Sequencing the first human genome cost about $1 billion and took 13 years. Fast forward two decades to today. You can pay a commercial genomics provider less than $1,000 to have your genome fully sequenced. And have it turned around in 2 to 4 weeks. The scientific community’s capabilities in and understanding of the field of genomics are developing at a blistering pace. Like other fast-moving sectors like tech, it is the government and regulators who are struggling to keep pace.

The news broke that the Human Genome Project had achieved this historic milestone back in 2000. The then Prime Minister, Tony Blair, said at the time: “We have to focus on the possibilities, develop them and then face up to the hard ethical and moral questions that are inevitably posed by such an extraordinary scientific discovery.”

What does it mean today?

Yet it is only now that we are really coming to terms with many of these legal and ethical questions. What happens to my genetic data once my DNA has been sequenced? Who has access to it? Will it be available to pharma companies? or used by insurance providers? All are valid and important questions for consumers using commercial genomics providers. But these are just the tip of the iceberg.

The House of Commons Science and Technology Committee, chaired by Norman Lamb MP, has a notable interest in the field. Last year it launched an inquiry to understand more about genomics and genome editing, noting parliamentary understanding of the field was somewhat lacking.

Now it is delving deeper beneath the surface to explore these legal and moral conundrums in more detail, launching a new inquiry last week to assess the regulations or standards that commercial genomic tests are currently subject to, and if any new or strengthened regulations should be introduced.

For providers of commercial testing, this is a golden opportunity. Not only to shape the conversation but also ensuring that this complex and emerging field can be understood by policymakers.

It was said at the time that “the deciphering of the book of life [is] a milestone in science”. The challenge for government is governing how and by whom it can be read.

See more articles by Andy Peel

sort news by category

Insight, Strategy, Impact,

#metoo, 2018, 2019, ABPI, accomodation, AI, Airport, alcohol, AMR, Antibiotics, artificial intelligence, Aviation, B2G, best practice, Brexit, bribery, careers, casual dining, childcare, children, climate change, communications, Comprehensive Spending Review, Conservatives, consumers, corporate affairs, corporate communications, corruption, CQC, culture, DHSC, Digital, DNA, due diligence, economics, education, Energy and Environment, environment, environmental, Equality, ESG, europe, feminism, Financial Services, fostering, General News, genetics, Genome Editing, genomics, governance, Government, government affairs, Harriet Harman, Health, health and social care, Health and Social Care Act 2012, health funding, healthcare, history, housing, housing policy, Human Genome, Human Genome Project, International Womens Day, investment, Investment Services, Investor, investors, Jess Phillips, job, local, local government, London, London Heathrow, luxury accomodation, Management Teams, Medical, Medical Funding, medicine, Medicines, member of parliament, Michelle Obama, millennials, mortage, MP, NHS, NHSE, NHSI, NICE, opinion, Outcomes Based Pricing, packaging, parliament, pharma, pharmaceuticals, pharmatech, Planning, Planning Communications, policy, Policy Risk, political, Political Due Diligence, political risk assessment, Politics, PR, prevention, PRI, pricing, Principles for Responsible Investment, private equity, private equity investment, procurement, Public Affairs, public procurement, Public Relations, rail, rail review, recycling, regulation, regulatory, rental, renting, responsible business, risk analysis, Science, select committee, select committee training, Sexual Harassment, social, social care, Social Care Green Paper, social housing, social responsbility, Strategic Communications, strategy, student, student accomodation, sustainbility, Technology, tenders, The Independent Group, The Labour Party, train, training, transport, travel, uk, UK Politics, waste, waste management, westminster, Woman, Woman-Led, women, Women in Politics, workforce,